Kincell Bio is a scientifically focused CDMO engineering cells into therapies and supporting immune cell programs including autologous and allogeneic CAR‑T, CAR‑NK and CAR‑M, as well as stem cell and iPSC products. Its platform offers personalized, responsive process development and manufacturing from early clinical through pivotal studies and product launch, with services in analytical and process development, GMP manufacturing, testing and release. The company operates manufacturing facilities in Research Triangle Park, NC and Gainesville, FL. Kincell plans to expand its cGMP capabilities and enhance process development services to support emerging cell therapy companies. The recent $22 million investment will accelerate those expansions and support development of innovative solutions tailored to the cell therapy market. Leadership additions, including the appointment of industry veteran Pete Buzy to the board, are positioned to bolster operational expertise as the company scales. Kincell Bio is a CDMO spun out of Inceptor Bio’s CMC, offering analytical development, process development, CMC consulting and early-stage GMP manufacturing for immune cell therapies. The company focuses on autologous and allogeneic CAR-T, CAR-NK and CAR-M programs. Kincell acquired a facility and a fully staffed team at its Gainesville site and plans to grow in Gainesville as well as Research Triangle Park, Boston and other customer locations. The company plans to establish in-house mRNA development and add GMP manufacturing capacity while forging partnerships for viral vector and plasmid DNA supply. Leadership includes CEO Bruce Thompson, Ph.D., who brings over 20 years of CMC strategy and cell therapy manufacturing experience, and board chair Shailesh Maingi of Kineticos Ventures. Kincell emerged from stealth with new funding to support its manufacturing and development expansion.

Total raised

$58M

Funding rounds

2

Latest round

Equity

Latest activity

May 2025